Oct
2026
Fiera Milano, Italy
Visit us
stand 6K74, Contract Manufacturing & Services
SKYEPHARMA
Exhibitor at CPHI Milan 2026
About Us
Categories
-
Country/Region:France
-
On CPHI since:2017
-
Certificates:3
-
Employees:100 - 249
Company types
Primary activities
Event information
CPHI Milan 2026
-
6 Oct 2026 - 8 Oct 2026
-
Fiera Milano, Italy
-
Visit us at stand 6K74, Contract Manufacturing & Services
Products Featured at CPHI Milan 2026
-
Product Early stage formulation Development & Process Design
We have extensive experience in solving complex formulation challenges. Our experts can apply our extensive range of proprietary technologies for immediate (IR) and modified (MR) / sustained, slow (SR) / controlled (CR) / extended (XR, ER) / pulsed / timed release as well as enteric and gastro reten... -
Product Clinical trial material (CTM) manufacturing and release
We offer capabilities for manufacturing of small and large scale clinical trial material (CTM) as well as characterization and release from phase 1 to phase 3. -
Product Manufacturing of complex and classic oral solid dosage forms
Manufacturing of classic and complex oral solid dosage forms: single layer tablets, multi-layer tablets, tab-in-tab, tab-in-caps, hard gel capsules, powder & pellets. -
Product Analytical Development and expertise
Our analytical experienced team support the pharmaceutical development during every phase of the development process. Analytical development transfer and validation, characterization capabilities, stability analysis, ICH Q3D (residuals solvent risk assesment), ICHQ3C (elemental impurities risk assesment... -
Product Scale-up and Quality by Design (QbD) processes
Skyepharma is experienced with the scale-up of complex oral solid dosage forms from laboratory to pilot-scale and full commercial scale manufacturing. We have powerfull compaction simulation tools ( STYL'One evolution) allowing to derisk and fasten scale-up steps.
Our capabilities :...
Skyepharma Production S.A.S Resources (1)
-
Whitepaper Recent development in complex tablet formulation design
In this article, Mathieu Degomme, PharmD, Pharmaceutical Development Project Manager, and Aline Moulin, PhD, Pharmaceutical Development Director, both of Skyepharma, outline three case studies from recent early-stage development programmes to illustrate what kind of complex tablets can be developed to meet specific target dissolution profiles for versatile applications.




